Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new, extensive systematic review has identified significant research gaps in the treatment of scrub typhus which could be improved by developing a database for individual participant data (IPD) to enable more detailed analyses to address important knowledge gaps such as the optimum dosing for children and to improve patient outcomes.

Women sitting in front of huts, traditional village in Southeast Asia © Pearl Gan

Scrub typhus is an acute febrile illness caused by intracellular bacteria from the genus Orientia. It is estimated that one billion people are at risk, with one million cases annually mainly affecting rural areas in Asia-Oceania. Scrub typhus is difficult to diagnose clinically without laboratory tests because it lacks reliable distinguishing features that differentiate it from other febrile illnesses prevalent in the endemic areas, such as typhoid fever, dengue fever and malaria. This difficulty in diagnosis is one of the main reasons for the current limited epidemiological knowledge on scrub typhus.

With scant and scattered data, it is difficult to identify the most at-risk populations, the regional distribution, and the optimal treatments to support disease control efforts. National treatment recommendations for scrub typhus vary or are simply not stated, and the absence of WHO recommendations illustrates the lack of high-quality supportive evidence for optimal treatments.

Researchers concluded there is substantial value in developing an IPD platform that will facilitate pooling and harmonisation of currently scattered data and enable in-depth investigation of priority research questions that can ultimately inform clinical practice and improve health outcomes for scrub typhus patients. The authors have called for scrub typhus to be recognised as a neglected tropical disease (NTD) by the WHO and the research community, which will help to increase awareness of the disease.

“The heterogeneous nature of the available data reflects the absence of consensus in treatment and research methodologies and poses a significant barrier to aggregating information across available published data without access to the underlying individual participant-level data (IPD). There is likely to be a substantial amount of data available to address knowledge gaps.” First author Kartika Saraswati

Read the publication 'Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform' on the PLOS Neglected Tropical Diseases website

The full story is available on the IDDO website

Similar stories

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.

Susie, Phaik Yeong, Richard and Paul among new full Oxford professors!

In the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.